Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2009 2
2010 3
2011 1
2013 2
2014 2
2015 3
2016 3
2017 4
2018 6
2020 8
2021 7
2022 11
2023 6
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative therapies for urological cancers.
Inokuchi J, Yokomizo A, Nishiyama N, Kitamura H, Eto M, Nishiyama H, Tomita Y. Inokuchi J, et al. Among authors: nishiyama n. Jpn J Clin Oncol. 2020 Apr 7;50(4):357-367. doi: 10.1093/jjco/hyaa013. Jpn J Clin Oncol. 2020. PMID: 32115649 Review.
Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer.
Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H; Japanese Urological Oncology Group. Shiota M, et al. Among authors: nishiyama n. Cancer Sci. 2022 Jul;113(7):2386-2396. doi: 10.1111/cas.15383. Epub 2022 May 17. Cancer Sci. 2022. PMID: 35485635 Free PMC article.
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T, Furubayashi N, Nakagawa T, Nishiyama N, Kitamura H, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Okajima E, Nakamura M. Negishi T, et al. Among authors: nishiyama n. Anticancer Res. 2021 Mar;41(3):1539-1545. doi: 10.21873/anticanres.14913. Anticancer Res. 2021. PMID: 33788747
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Ito K, Kita Y, Yokomizo A, Miki J, Yoshio Y, Matsumoto H, Segawa T, Karashima T, Nishiyama N, Imai K, Suekane S, Nagasawa S, Higashi S, Nishiyama H, Kitamura H, Kobayashi T. Ito K, et al. Among authors: nishiyama n. Cancer Med. 2023 Feb;12(3):2325-2332. doi: 10.1002/cam4.5057. Epub 2022 Jul 21. Cancer Med. 2023. PMID: 35864744 Free PMC article.
Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Matsumura Y, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Nishimura N, et al. Among authors: nishiyama n. Int J Urol. 2022 Mar;29(3):242-249. doi: 10.1111/iju.14759. Epub 2021 Dec 13. Int J Urol. 2022. PMID: 34902876
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Numakura K, et al. Among authors: nishiyama n. Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. Cancers (Basel). 2023. PMID: 37046663 Free PMC article.
Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.
Iida K, Miyake M, Murakami K, Komiyama M, Okajima E, Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K. Iida K, et al. Among authors: nishiyama n. Int J Clin Oncol. 2021 Nov;26(11):2104-2112. doi: 10.1007/s10147-021-01988-8. Epub 2021 Jul 27. Int J Clin Oncol. 2021. PMID: 34313904
Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.
Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. J Geriatr Oncol. 2022 Jan;13(1):88-93. doi: 10.1016/j.jgo.2021.07.002. Epub 2021 Jul 6. J Geriatr Oncol. 2022. PMID: 34238726
58 results